Weston, MA, United States of America

Susan Korsmeyer, Legal Representative


Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 175(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Susan Korsmeyer: Innovator in Peptide Research

Introduction

Susan Korsmeyer is a prominent legal representative and inventor based in Weston, MA (US). She has made significant contributions to the field of peptide research, holding a total of 3 patents. Her work focuses on developing novel polypeptides and inhibitors that have potential therapeutic applications.

Latest Patents

Korsmeyer's latest patents include "Stabilized alpha helical peptides and uses thereof" and "Inhibitors of Taspase1 protease activity." The first patent describes polypeptides that incorporate cross-linking moieties, which help constrain their secondary structure. These polypeptides can be utilized in treating diseases characterized by excessive or inadequate cellular death. The second patent introduces Taspase1, a novel protease involved in the cleavage of the MLL protein, essential for proper HOX gene regulation. This patent also outlines diagnostic methods and inhibitors that can be used to treat cancers, such as leukemia.

Career Highlights

Throughout her career, Korsmeyer has worked with esteemed institutions, including Dana-Farber Cancer Institute Inc. and Harvard College. Her research has significantly advanced the understanding of peptide functionality and its implications in medical treatments.

Collaborations

Some of her notable coworkers include Stanley J. Korsmeyer and Loren D. Walensky, who have also contributed to the field of cancer research and peptide studies.

Conclusion

Susan Korsmeyer's innovative work in peptide research and her contributions to the understanding of protease activity have positioned her as a key figure in the scientific community. Her patents reflect her commitment to advancing medical science and improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…